Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03036865 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects
A Phase 1 study, sponsored by Boston Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT03036865 is a Phase 1 study that has completed, run by Boston Pharmaceuticals. The registered enrollment target is 61 participants.
The verdict
NCT03036865, a Phase 1 study, has completed, sponsored by Boston Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
Study BOS161721-01 is a randomized, single center, double-blind, placebo-controlled trial conducted to study the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending intravenous (IV) and subcutaneous (SC) doses of BOS161721 or placebo in healthy adult male and female participants.
Interventions
- DRUG Placebo
- DRUG BOS161721
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-01 |
| Est. Completion | 2018-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03036865
The ClinicalTrials.gov registry entry for NCT03036865 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03036865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03036865 about?
NCT03036865 is a clinical study titled "Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects". Study BOS161721-01 is a randomized, single center, double-blind, placebo-controlled trial conducted to study the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending intravenous (IV) and subcutaneous (SC) doses of BOS161721 or placebo in healthy adult male and female particip...
What is the current status of trial NCT03036865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2017-01. Estimated completion is 2018-04-27.
What interventions are being tested in trial NCT03036865?
The interventions under investigation include: Placebo (DRUG), BOS161721 (DRUG).
Who is sponsoring clinical trial NCT03036865?
This trial is sponsored by Boston Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.